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ties were very mild: 6% G3/4 febrile neutropenia, 3% infection, and 
3% rash. No treatment-related deaths occurred. 
Conclusion: Adjuvant CG in patients with completely resected 
NSCLC is well tolerated, and treatment compliance is very good.
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Background: In an era of ever evolving, promising new therapies for 
advanced non small cell lung cancer, early predictors of response to 
therapy, are needed. We evaluated early variations in CYFRA 21-1 
serum levels of patients with advanced NSCLC receiving ﬁrst line che-
motherapy and correlated the results with objective tumor response. 
Patients and Methods: 29 consecutive, previously untreated, patients 
of advanced non small cell lung cancer,excluding those with brain me-
tastases, with measurable disease on CT scan were evaluated. All pa-
tients were treated with conventional systemic chemotherapy, although 
the choice of chemotherapy was left to the discretion of the treating 
physicians. Serum samples were obtained immediately before the start 
of 1st and 2nd cycles of chemotherapy. CYFRA 21-1 was measured with 
an electrochemiluminescense immunoassay on an automatic analyzer 
(Elecsys 2000; Roche Diagnostics). Response was evaluated using 
Response evaluation criteria in solid tumors (RECIST) criteria.
Results: 10 patients had partial response, 9 patients had stable disease 
and 9 had progressive disease. None of the patients had complete 
response. 21/29 i.e. 72 % patients had an elevated baseline value of 
CYFRA 21-1. 62 % patients (18/29) had a decrease in CYFRA 21-1 
after 1 cycle of chemotherapy. The average reduction in the 2nd reading 
was irrespective of whether baseline value was normal or not. The 
average reduction was statistically signiﬁcant (P = 0.002; 95% CI, from 
0.8369 to 3.49464; paired sample t test). 8 out of 10 (80%) patients 
with partial response had a reduction in their 2nd reading of. CYFRA 
(P= 0.019; 95% CI, from 0.81965 to 7.20035; paired sample t test) 
which was signiﬁcant. We also observed that 6/9 (66%) patients whose 
disease remains stable also had a decrease in their subsequent reading 
(P=0.0106; 95% CI, from - 0.44942 to 3.82720; paired sample t test), 
though it was not signiﬁcant statistically. Although 5 out of 9 (55%) 
patients, who had an increase in their 2nd reading had progressive 
disease, but it was not statistically signiﬁcant (P= 0.537; 95% CI, from 
-1.20021 to 2.13354; paired sample t test). 14 out of 19 (73%) who ei-
ther had partial response or had stable disease, had a reduction in their 
2nd value of CYFRA and was signiﬁcant statistically (P 0.004; 95% CI, 
from 0.74792 to 3.50208; paired sample t test). We also observed that 
except for 1 patient, all patients who had a decrease of 42% or more, 
were those who had either responded to chemotherapy or had stable 
disease (P 0.001), which was statistically signiﬁcant.
Conclusion: We conclude that monitoring of serum marker CYFRA 
21-1, early during ﬁrst-line chemotherapy may be a useful prognostic 
tool for evaluation of early tumor response in patients with advanced 
NSCLC
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Background: Stage IIIB and IV non-small cell lung cancer (NSCLC) 
is incurable and treatment with chemotherapy aims at reducing 
symptoms and prolonging survival. Life time expectancy is short and 
any treatment should allow a maximum of patient autonomy to fulﬁll 
personal wishes and preferences. It has a major inﬂuence on every 
day life to receive chemotherapy; either positive with attention and 
care or negative with distressing time spend at the clinic. Vinorelbine 
is available in an oral (PO) or intravenous (IV) formulation. The PO 
treatment can be administered at home without the need for an IV line 
at the clinic. The opportunity could be resource sparing for the health 
care system and for patient transportation, but little is known about the 
patients’ preference. The aim of the present study was to explore the 
subjective reasons for patients choosing PO or IV treatment in a clinical 
setup.
Methods: The study included 61 patients with stage IIIB or IV NSCLC 
in a previously reported randomized cross-over trial. The patients were 
randomly allocated to two cycles of IV vinorelbine followed by two 
cycles of PO vinorelbine or the opposite sequence. Each cycle was 
combined with IV carboplatin day one and vinorelbine was given day 
one and eight. Antiemetics were added both day one and eight. After re-
ceiving four cycles, the patients had a free choice of IV or PO vinorel-
bine for the last two cycles. This choice was regarded as the patient’s 
preference. A questionnaire was ﬁlled in after four cycles to explore 
and quantify the subjective reasons for selecting a treatment. Sixteen 
questions were asked on a ﬁve-point scale. The median answers were 
used to estimate the group opinion and comparisons between groups 
were done by Wilcoxon test.
Results: Forty-three patients completed four cycles and made a 
choice for IV vinorelbine (n=11, 26%) or PO vinorelbine (n=32, 74%) 
(p<0.001) independently of treatment arm (p=0.94) and sex (p=0.94). 
The median age for patients choosing IV or PO was 59 and 63 years, 
respectively (p=0.24). Side effects reported after each cycle did not 
correlate with the patients’ preference. Forty patients ﬁlled in the ques-
tionnaire. In general, it was the subjective conception that pills and IV 
treatment had equal efﬁciency in treating the cancer. Patients with pref-
erence for IV treatment agreed that pills had more side effects than IV, 
whereas patients preferring PO did not ﬁnd any differences. The daily 
life was less affected by pills than infusions in patients with preference 
for PO but not for the IV group. Patients who chose IV vinorelbine 
were more concerned about the risk of forgetting the pills, vomiting up 
the pills, and taking them at home.
Conclusions: In a randomized cross-over study where patients experi-
enced both IV and PO vinorelbine in combination with IV carboplatin, 
the major part (74%) preferred PO treatment.
Although not reﬂected in toxicity grading during the study, the major 
subjective reason for choosing IV vinorelbine was more side effects 
with pills and patients choosing PO vinorelbine found that the pills 
affected daily life less.
